Breaking News
Get 55% Off 0
Final hours! Save up to 55% OFF InvestingPro
CLAIM SALE
Close

Blackrock Global Funds - World Healthscience Fund A2 (0P0000VHO6)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
63.240 -0.230    -0.36%
20/12 - Closed. Currency in EUR
Type:  Fund
Market:  Luxembourg
Issuer:  BlackRock (Luxembourg) SA
ISIN:  LU0171307068 
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 6.39B
BlackRock Global Funds - World Healthscience Fund 63.240 -0.230 -0.36%

Blackrock Global Funds - World Healthscience Fund A2 Overview

 
On this page you'll find an in-depth profile of Blackrock Global Funds - World Healthscience Fund A2. Learn about the key management, total assets, investment strategy and contact information of 0P0000VHO6 among other information.
Category

Sector Equity Healthcare

Total Assets

6.39B

Expenses

1.81%

Inception Date

Apr 06, 2001

Investment Strategy

The Fund seeks to maximise total return and invest in a manner consistent with the principles of environmental, social and governance (“ESG”) investing. The Fund invests globally at least 70% of its total assets in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. Currency exposure is flexibly managed.

Contact Information

Address 35 A, avenue J.F. Kennedy,
Luxembourg, L-1855
Luxembourg
Phone +44 20 77433000
Fax Amsterdam

Top Executives

Name Title Since Until
Xiang Liu Director 2020 Now
Biography Xiang Liu, PhD, Director, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the medical devices & supplies sector. Prior to joining BlackRock in 2008, Mr. Liu was a partner and biotech analyst at Mehta Partners. From 2002 to 2005, he was a Director in the corporate development department at Cubist Pharmaceuticals. Mr. Liu began his investment career in 2000 at the Boston Consulting Group as a Healthcare consultant. Mr. Liu earned a BS degree in Chemistry from the University of Science & Technology, China in 1993, a PhD degree in Chemistry from Yale University in 1997, and a MBA degree in finance, strategy, and accounting from the University of Chicago in 2000.
Erin Xie Managing Director 2011 Now
Biography Erin Xie, PhD, Managing Director and portfolio manager, is the head of the Health Sciences team, part of BlackRock’s Active Equity Group. She is the lead portfolio manager for the Health Sciences equity portfolios. Ms. Xie's service with the firm dates back to 2001, including her years with State Street Research & Management (SSRM), which merged with BlackRock in 2005. At SSRM, she was a Senior Vice President and portfolio manager responsible for managing the State Street Health Sciences Fund. Prior to joining State Street Research in 2001, Ms. Xie was a research associate with Sanford Bernstein covering the pharmaceutical industry from 1999. From 1994 until 1997, she was a post doctoral research scientist at Columbia University. Ms. Xie earned a BS degree in chemistry from Beijing University in 1988, a PhD degree in Biochemistry from the University of California, Los Angeles, in 1993 and a MBA degree from the Massachusetts Institute of Technology Sloan School of Management in 1999.
Jeff Lee - 2020 2023
Biography Jeffrey Lee, Director, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the healthcare providers and services sector. Prior to joining BlackRock in 2011, Mr. Lee was a member of the healthcare investment team at Duquesne Capital Management where he covered provider and service companies. From 2006 to 2008, Mr. Lee was an healthcare private equity associate at Altaris Capital Partners where he sourced and analyzed equity transactions for public and private healthcare companies. Prior to 2006, Mr. Lee was an analyst at Citigroup within the healthcare finance and investment banking group where he valued and helped structured financing for managed care providers, hospital companies and other large healthcare systems. Mr. Lee earned a BA degree in economics, cum laude, from Princeton University in 2004.
Thomas P. Callan Managing Director 2011 2017
Biography Thomas P. Callan, CFA, Managing Director and senior portfolio manager, is head of BlackRock's Global Opportunities equity team. He oversees the team's investment process, leads the team's Investment Strategy Group, and provides portfolio and risk management oversight for all of the team's products. In addition, Mr. Callan is a member of BlackRock's Leadership Committee. Mr. Callan's service with the firm dates back to 1988, including his years with PNC Asset Management Group, which was integrated with BlackRock in 1998. He started as a health care analyst for PNC's mutual fund group and later served as an international equity analyst. Mr. Callan began his investment career at PNC Bank as a personal trust portfolio manager in 1988. Mr. Callan earned a BA degree in economics, with honors, from Boston College in 1981.
Bob Hodgson - 2005 2011
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P0000VHO6 Comments

Write your thoughts about Blackrock Global Funds - World Healthscience Fund A2
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email